Neovasc - NVCN Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVCN shares.
View NVCN analyst ratings or view top-rated stocks.

Neovasc's stock was trading at $11.7150 on January 1st, 2022. Since then, NVCN shares have decreased by 29.7% and is now trading at $8.24.
View the best growth stocks for 2022 here.

Neovasc saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 25,400 shares, an increase of 16.0% from the October 31st total of 21,900 shares. Based on an average daily volume of 6,300 shares, the days-to-cover ratio is currently 4.0 days. Approximately 1.0% of the company's stock are short sold.
View Neovasc's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our NVCN earnings forecast.

Neovasc Inc. (NASDAQ:NVCN) posted its quarterly earnings results on Tuesday, November, 9th. The medical equipment provider reported ($2.75) earnings per share for the quarter, missing the consensus estimate of ($2.25) by $0.50. The medical equipment provider earned $0.70 million during the quarter, compared to analyst estimates of $1.20 million. Neovasc had a negative trailing twelve-month return on equity of 76.22% and a negative net margin of 1,077.37%. During the same period in the prior year, the firm earned ($12.75) earnings per share.

Neovasc shares reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Protalix BioTherapeutics (PLX), Palatin Technologies (PTN), Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Shares of NVCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVCN stock can currently be purchased for approximately $8.24.

Neovasc (NASDAQ:NVCN) has a market capitalization of $22.58 million and generates $2.55 million in revenue each year. The medical equipment provider earns $-24,890,000.00 in net income (profit) each year or ($12.29) on an earnings per share basis.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The official website for the company is www.neovasc.com. The medical equipment provider can be reached via phone at (604) 270-4344, via email at investors@neovasc.com, or via fax at 604-270-4384.